Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses.
Ripperda. Thomas T; Yu. Yangsheng Y; Verma. Atul A; Klug. Elizabeth E; Thurman. Michellie M; Reid. St Patrick SP; Wang. Guangshun G
Key Findings
- A faster, single‑step design approach identified antiviral peptide parameters
- Engineered peptide DFTavP1 blocks Ebola virus entry
- Engineered peptide DDIP1, like LL‑37, blocks both Ebola and SARS‑CoV‑2
- Changing key peptide features reduces antiviral activity
Practical Outcomes
- These findings hint that custom antiviral peptides could become future supplements, but more testing is needed before anyone can safely try them. No dosage, safety, or real‑world protocols are provided yet.
Summary
Scientists used a new computer method to quickly design short proteins that can stop viruses like Ebola and COVID‑19, similar to a natural human peptide called LL‑37. The engineered peptides showed they can block the virus from entering cells, but the work is still early and not ready for personal use.
Abstract
The rapid mutations of viruses such as SARS-CoV-2 require vaccine updates and the development of novel antiviral drugs. This article presents an improved database filtering technology for a more effective design of novel antiviral agents. Different from the previous approach, where the most probable parameters were obtained stepwise from the antimicrobial peptide database, we found it possible to accelerate the design process by deriving multiple parameters in a single step during the peptide amino acid analysis. The resulting peptide DFTavP1 displays the ability to inhibit Ebola virus. A deviation from the most probable peptide parameters reduces antiviral activity. The designed peptides appear to block viral entry. In addition, the amino acid signature provides a clue to peptide engineering to gain cell selectivity. Like human cathelicidin LL-37, our engineered peptide DDIP1 inhibits both Ebola and SARS-CoV-2 viruses. These peptides, with broad antiviral activity, may selectively disrupt viral envelopes and offer the lasting efficacy required to treat various RNA viruses, including their emerging mutants.
Study Information
pubmed
2022
2022-04-24T00:00:00.000Z
10.3390/ph15050521
7
44